Allan Camaisa

CIK 1990674 · CEO and Chairman of the Board · last filed 2025-12-16

Allan Camaisa is a CEO and Chairman of the Board who has filed 5 SEC Form 4 insider transactions across 2 companies since 2024. The most recent filing shows the insider sold $1.2K of CLDI on Dec 16, 2025. Across all open-market trades the lifetime net is −$17.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $554 across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$554

Companies

2

Total Filings

5

Lifetime Open-Market Net

-$17.4K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
CLDI	CEO and Chairman of the Board	5,157	$0.11	$554	-$17.4K	2	2025-12-16
Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted	CEO and Chairman of the Board	76,712	$0.01	$445	$0	3	2024-09-30

Recent Filings

5 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2025-12-16	CLDI	Sell (S)	−850	-$1.2K	EDGAR
2024-12-18	CLDI	Sell (S)	−10,000	-$16.2K	EDGAR
2024-09-30	Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted	Grant (A)	+70,155	$80.7K	EDGAR
2024-06-20	Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted	Grant (A)	—	$0	EDGAR
2024-01-04	Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted	Grant (A)	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.